Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of Abcertin and Cerezyme in Healthy Volunteers
NCT04787887Phase 1Completed
- Sponsor
- ISU Abxis Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Sep 2020
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of imiglucerase in Gaucher disease (GD) (2 arms), sponsored by ISU Abxis Co., Ltd. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity. Started Jan 2020; status: completed.
02
Drugs
imiglucerase
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on NCT04787887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787887.